

Iowa Department of Human Services

FAX Completed Form To 1 (800) 574-2515

Provider Help Desk 1 (877) 776-1567

Request for Prior Authorization CHOLIC ACID (CHOLBAM®)

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name Address		Phone
Prescriber must complete all informa	tion above. It must be legible, correct, and c	omplete or form will be returned.
Pharmacy NPI	Pharmacy fax	NDC

Prior authorization is required for cholic acid (Cholbam[®]). Payment will be considered under the following conditions:

- 1) Is prescribed by a hepatologist or pediatric gastroenterologist; and
- 2) Is prescribed for a diagnosis of bile acid synthesis disorder due to a single enzyme defect (SED) including:
 - 3-beta-hydroxy-delta-5c27-steroid oxidoreductase deficiency (3-βHSD),
 - Aldo-keto reductase 1D1 (AKR1D1),
 - Alpha-methylacyl-CoA racemase deficiency (AMACR deficiency),
 - Sterol 27-hydroxylase deficiency (cerebrotendinous xanthomatosis [CTX]),
 - Cytochrome P450 7A1 (CYP7A1),
 - 25-hydroxylation pathway (Smith-Lemli-Opitz), OR
- Is prescribed as an adjunctive treatment of peroxisomal disorder (PD) in patients who exhibit manifestations
 of liver disease, steatorrhea, or complications from fat soluble vitamin absorption. Peroxisomal disorders
 include Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), or infatile refsum disease (IRD);
 and
- 4) Diagnosis is confirmed by mass spectrometry or other biochemical testing or genetic testing (attach results);
- 5) Baseline liver function tests are taken prior to initiation of therapy (AST. ALT, GGT, ALP, total bilirubin, INR) and provided with request; and
- 6) Patient must have elevated serum aminotransferases (AST and ALT) with normal serum gamma glutamyltransferase (GTT); and
- 7) Patient is at least 3 weeks old.

When criteria for coverage are met, an initial authorization will be given for 3 months. Additional approvals will be granted for 12 months at a time requiring documentation of response to therapy by meeting two of the following criteria:

- Body weight has increased by 10% or is stable at ≥50th percentile,
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 50 U/L or baseline levels reduced by 80%,
- Total bilirubin level reduced to ≤1mg/dL.

470-5391 (4/16) Page 1 of 2

Request for Prior Authorization CHOLIC ACID (CHOLBAM®)

(PLEASE PRINT - ACCURACY IS IMPORTANT)

<u>Non</u>	-Preferred							
	Cholbam							
	Strength		Dosage Instructions Qu		uantity	Days Supply		
Diag	gnosis:							
	Bile Acid Synthesis Disorder due to SED							
	O 3β-HSD	O AKR1D1	O AMACR deficiency	O CTX	O CYP7A1	O Smith-Lemli-Opitz		
	Peroxisomal Disorder (PD)							
	O ZWS	O NALD	O IRD					
	Other:							
	Attach results of diagnosis confirmation by mass spectrometry, biochemical testing, or genetic testing							
	Provider specialty:							
	Attach baseline liver function tests prior to initiation of therapy (AST, ALT, GGT, ALP, total bilirubin, INR)							
	Renewal requests: Provide documentation of adequate response to treatment by meeting two of the following criteria (attach lab results and/or chart notes):							
	O Body weight has increased by 10% or is stable at ≥50 th percentile							
	○ ALT or AST < 50 U/L or baseline levels reduced by 80%							
 ○ Total bilirubin level reduced to ≤ 1mg/dL 								
Atta	nch lab results	s and other do	cumentation as necessa	ry.				
Prescriber signature (Must match prescriber listed above.)				Date of subm	ission			

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

470-5391 (4/16) Page 2 of 2